Clinical Lung Cancer
Scope & Guideline
Innovative insights for the future of pulmonary medicine.
Introduction
Aims and Scopes
- Clinical Trials and Therapeutics:
The journal extensively covers clinical trials assessing novel therapies, including immunotherapy, targeted therapy, and combinations thereof, particularly in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). - Genomic and Molecular Characterization:
Research articles focus on the genomic landscape of lung cancers, including mutations, fusions, and biomarkers that guide personalized treatment options. - Real-World Outcomes and Patient-Centered Care:
An emphasis on real-world outcomes, patient preferences, and quality of life in lung cancer management reflects the journal’s commitment to patient-centered approaches. - Innovative Diagnostic Techniques:
Papers discussing advancements in diagnostic tools such as liquid biopsies, imaging techniques, and molecular profiling underscore the journal's focus on early detection and treatment stratification. - Multidisciplinary Management Strategies:
The journal promotes studies that incorporate multidisciplinary teams in the treatment of lung cancer, highlighting the collaboration between surgical, medical, and radiation oncologists.
Trending and Emerging
- Immunotherapy and Combination Therapies:
The rise of studies evaluating immunotherapy, particularly checkpoint inhibitors, and their combinations with other treatments, signifies a major trend in lung cancer treatment. - Real-World Evidence Studies:
There is an increasing emphasis on real-world evidence that captures the effectiveness of treatments in diverse populations, providing insights that complement clinical trial data. - Artificial Intelligence and Machine Learning Applications:
The integration of AI and machine learning in predicting treatment outcomes and personalizing therapy is an emerging focus, reflecting technological advancements in healthcare. - Patient-Reported Outcomes and Quality of Life Assessments:
Research focusing on patient-reported outcomes and overall quality of life is gaining importance, highlighting the need for holistic patient care. - Molecular Targeted Therapies for Rare Mutations:
An increase in studies addressing targeted therapies for less common genetic mutations in lung cancer, such as MET and RET alterations, indicates a trend towards more personalized treatment strategies.
Declining or Waning
- Traditional Chemotherapy Approaches:
There has been a noticeable decrease in studies focusing solely on traditional chemotherapy regimens, as the field increasingly shifts towards personalized medicine and targeted therapies. - Basic Science Research:
Research that delves into the basic science of lung cancer biology, while still important, appears less frequently as clinical applications and trials take precedence. - Surgical Techniques Without Context:
Papers discussing surgical techniques in isolation, without integration into broader treatment strategies or multidisciplinary approaches, are becoming less common. - Epidemiological Studies:
There is a waning interest in purely epidemiological studies without a clear clinical or therapeutic implication, as the focus shifts to actionable insights and clinical applications. - Single-Agent Studies:
Research centered on single-agent therapies is declining in favor of combination therapies that increase efficacy and address resistance mechanisms.
Similar Journals
Breathe
Exploring new horizons in lung health.Breathe, published by the European Respiratory Society Journals Ltd, is a prominent open-access journal dedicated to advancing the field of pulmonary and respiratory medicine. With an ISSN of 1810-6838 and an E-ISSN of 2073-4735, this journal has been contributing to scholarly discourse since 2008. Nestled in the United Kingdom, it serves as a vital platform for researchers, clinicians, and educators, particularly in the areas of respiratory pathophysiology, diagnostic methods, and therapeutic interventions. Currently classified in the third quartile (Q3) for pulmonary and respiratory medicine, Breathe ranks 91st out of 155 in Scopus, reflecting its growing influence in the discipline. The journal aims to publish high-quality, peer-reviewed research that fosters collaboration and innovation in lung health, making significant strides toward improving patient outcomes. Whether you are a seasoned professional or an up-and-coming researcher, Breathe offers a wealth of knowledge and resources to support your work in this crucial area of medicine.
THORAX
Uncovering breakthroughs in lung health and disease.THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.
EUROPEAN RESPIRATORY JOURNAL
Advancing the Frontiers of Respiratory MedicineThe EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.
Thoracic Cancer
Innovating the future of lung cancer treatment.Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.
Oncology Research and Treatment
Fostering dialogue for a brighter future in oncology.Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.
JTO Clinical and Research Reports
Connecting Researchers and Clinicians for Impactful DiscoveriesJTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.
CANCER INVESTIGATION
Pioneering insights in oncology for a healthier tomorrow.CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.
JOURNAL OF CLINICAL ONCOLOGY
Pioneering breakthroughs in oncology and patient care.Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.
Journal of Thoracic Disease
Empowering healthcare professionals with vital research.Welcome to the Journal of Thoracic Disease, a premier scholarly journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by AME PUBLISHING COMPANY in Hong Kong, this journal has established itself as a critical platform for the dissemination of innovative research and clinical advancements since its inception in 2009. With an impressive Q2 ranking in the Scopus category of Pulmonary and Respiratory Medicine, it is recognized for its contribution to the academic community, featuring a broad range of original research, reviews, and case studies that address contemporary challenges in thoracic disease management. The journal is committed to Open Access principles, ensuring that high-quality research is readily available to a global audience, further enhancing its impact factor and reach. Researchers, healthcare professionals, and students alike will find invaluable insights within its pages, making Journal of Thoracic Disease an essential resource for those invested in the respiratory health domain.
Current Pulmonology Reports
Exploring the latest innovations in pulmonology.Current Pulmonology Reports, published by SPRINGER, stands as a vital resource in the realm of respiratory health, delivering peer-reviewed research that informs clinical practices and advances understanding within the field of pulmonology. With an E-ISSN of 2199-2428, this journal captures the latest findings and technological innovations pertinent to respiratory diseases, treatment protocols, and patient management strategies. Although currently classified as non-open access, it ensures robust dissemination of significant research contributions which are essential for professionals and scholars alike. The journal's objective is not only to foster a deeper understanding of lung health issues but also to bridge the gap between research and application, thereby impacting real-world practices. As the demand for comprehensive studies in pulmonology continues to grow, Current Pulmonology Reports seeks to maintain its position as a premier outlet for quality research, ultimately bettering outcomes in respiratory medicine.